Correlation Between Halozyme Therapeutics and Zai Lab
Can any of the company-specific risk be diversified away by investing in both Halozyme Therapeutics and Zai Lab at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Halozyme Therapeutics and Zai Lab into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Halozyme Therapeutics and Zai Lab, you can compare the effects of market volatilities on Halozyme Therapeutics and Zai Lab and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Halozyme Therapeutics with a short position of Zai Lab. Check out your portfolio center. Please also check ongoing floating volatility patterns of Halozyme Therapeutics and Zai Lab.
Diversification Opportunities for Halozyme Therapeutics and Zai Lab
-0.49 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Halozyme and Zai is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Halozyme Therapeutics and Zai Lab in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zai Lab and Halozyme Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Halozyme Therapeutics are associated (or correlated) with Zai Lab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zai Lab has no effect on the direction of Halozyme Therapeutics i.e., Halozyme Therapeutics and Zai Lab go up and down completely randomly.
Pair Corralation between Halozyme Therapeutics and Zai Lab
Given the investment horizon of 90 days Halozyme Therapeutics is expected to under-perform the Zai Lab. But the stock apears to be less risky and, when comparing its historical volatility, Halozyme Therapeutics is 1.07 times less risky than Zai Lab. The stock trades about -0.08 of its potential returns per unit of risk. The Zai Lab is currently generating about 0.17 of returns per unit of risk over similar time horizon. If you would invest 1,976 in Zai Lab on September 4, 2024 and sell it today you would earn a total of 944.00 from holding Zai Lab or generate 47.77% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Halozyme Therapeutics vs. Zai Lab
Performance |
Timeline |
Halozyme Therapeutics |
Zai Lab |
Halozyme Therapeutics and Zai Lab Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Halozyme Therapeutics and Zai Lab
The main advantage of trading using opposite Halozyme Therapeutics and Zai Lab positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Halozyme Therapeutics position performs unexpectedly, Zai Lab can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zai Lab will offset losses from the drop in Zai Lab's long position.Halozyme Therapeutics vs. Agios Pharm | Halozyme Therapeutics vs. Insmed Inc | Halozyme Therapeutics vs. Ultragenyx | Halozyme Therapeutics vs. Biomarin Pharmaceutical |
Zai Lab vs. C4 Therapeutics | Zai Lab vs. Erasca Inc | Zai Lab vs. Cullinan Oncology LLC | Zai Lab vs. Legend Biotech Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Complementary Tools
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |